Datafin

Data-driven stock analysis platform for global investors.

Sitemap
HomeScreenerValuationSector Analysis
Resources
LibraryDatafin GuideMetric MethodologyValuation MethodologiesFAQPricingWho Is Datafin?Communication
Legal
Privacy PolicyTerms of UseCookie PolicyKVKK NoticeRefund Policy
Data Sources

Financial data sourced from official regulatory filings and verified market data providers. Metrics calculated using GAAP/IFRS standards.

Disclaimer

The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

Investment decisions involve risk. Verify data independently and consult a licensed advisor when needed.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved.

Last updated: April 2026

HLN FINANCIAL STATEMENTS

Haleon PLC — balance sheet, income statement and cash flow trends

HLNHaleon PLC

🇬🇧 UK · LSE · Healthcare · Drug Manufacturers - Specialty & Generic

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income
05 B10 B20212022202320242025

Profit Funnel

Q3 2025 · TTM
Revenue8.2 B £Gross Profit5.1 B £ · 61%Operating Income1.6 B £ · 19%Pre-tax Income1.4 B £ · 17%Net Income1 B £ · 13%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue8.2 B £-26.7%
Gross Profit5.1 B £-28.5%
Operating Income1.6 B £-27.0%
EBITDA2.1 B £-28.0%
Net Income1 B £-14.2%

Peer Comparison· Drug Manufacturers - Specialty & Generic

CompanyRev. GrowthGross MarginEBITDA MarginNet Margin
HLN-26.7%61.5%25.2%12.6%
EOLS9.6%65.5%-4.6%-14.4%
EBS-29.9%44.4%22.8%-1.3%
TLRY3.8%27.7%-156.2%-158.8%
DEVA7.7%32.5%12.0%-4.4%
ORGO11.9%70.4%7.3%-0.1%
Industry median7.5%60.6%18.2%4.0%
CompanyRev. GrowthGross MarginEBITDA MarginNet Margin
HLN-26.7%61.5%25.2%12.6%
HIK7.4%41.4%20.0%12.0%
Industry median7.5%60.6%18.2%4.0%

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
-20 B020 B40 B20212022202320242025

Capital Structure

Q3 2025
Total Assets32.6 B
  • Equity16.4 B £50%
  • Current Liabilities4.9 B £15%
  • Long-term Liabilities11.2 B £34%

Key Figures

YoY change
Total Assets32.6 B £—
Total Liabilities16.1 B £—
Total Equity16.4 B £-1.7%
Cash & ST Investments1.3 B £+149.3%
Total Debt8.6 B £—
Net Debt7.3 B £—

Peer Comparison· Drug Manufacturers - Specialty & Generic

CompanyCurrent RatioDebt/EquityNetDebt/EBITDAEquity/Assets
HLN0.9252.3%3.5050.3%
EOLS2.04-573.0%-8.20-13.0%
EBS4.29109.7%2.6839.6%
TLRY2.7920.4%-0.0775.1%
DEVA2.0023.1%0.8969.9%
ORGO3.5318.6%-0.5773.3%
Industry median2.2246.3%1.2445.7%
CompanyCurrent RatioDebt/EquityNetDebt/EBITDAEquity/Assets
HLN0.9252.3%3.5050.3%
HIK1.8261.8%1.8745.7%
Industry median2.2246.3%1.2445.7%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
01 B2 B20212022202320242025

Cash Flow Bridge

Q3 2025 · TTM
-1 B01 B1 B £Operating-76 M £Investing-2.5 B £Financing-1.6 B £Net Change

Key Figures

YoY change
Operating Cash Flow1 B £—
Capital Expenditures96 M £—
Free Cash Flow931 M £—
Dividends Paid-415 M £—

Peer Comparison· Drug Manufacturers - Specialty & Generic

CompanyCF MarginFCF MarginCapEx RatioCF/Net Income
HLN12.5%11.3%1.2%99.0%
EOLS-12.1%-14.4%2.3%84.3%
EBS21.9%20.0%1.9%-1,720.9%
TLRY-5.6%-8.3%3.8%3.5%
DEVA25.8%19.3%12.8%-590.3%
ORGO6.0%3.3%2.7%-10,828.5%
Industry median15.2%11.6%2.5%84.3%
CompanyCF MarginFCF MarginCapEx RatioCF/Net Income
HLN12.5%11.3%1.2%99.0%
HIK11.6%5.8%5.8%96.8%
Industry median15.2%11.6%2.5%84.3%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on HLN

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 7, 26. This content is for informational purposes only and is not investment advice.